The China Mail - Drew Weissman, Nobel-winning mRNA pioneer

USD -
AED 3.673042
AFN 69.824515
ALL 86.361437
AMD 382.900119
ANG 1.789679
AOA 917.503981
ARS 1134.355808
AUD 1.539409
AWG 1.80125
AZN 1.70397
BAM 1.720368
BBD 2.015745
BDT 121.599156
BGN 1.72155
BHD 0.376919
BIF 2971.19233
BMD 1
BND 1.28425
BOB 6.898887
BRL 5.646704
BSD 0.998373
BTN 85.101816
BWP 13.401064
BYN 3.267186
BYR 19600
BZD 2.005366
CAD 1.37365
CDF 2865.000362
CHF 0.821469
CLF 0.024533
CLP 941.452258
CNY 7.204304
CNH 7.172595
COP 4170.119189
CRC 507.806659
CUC 1
CUP 26.5
CVE 96.991688
CZK 21.866604
DJF 177.78071
DKK 6.565104
DOP 58.961165
DZD 132.208295
EGP 49.88433
ERN 15
ETB 135.150899
EUR 0.879504
FJD 2.251804
FKP 0.739085
GBP 0.738798
GEL 2.740391
GGP 0.739085
GHS 11.031359
GIP 0.739085
GMD 72.000355
GNF 8648.45846
GTQ 7.66328
GYD 208.866605
HKD 7.83305
HNL 25.986718
HRK 6.629704
HTG 130.632889
HUF 355.270388
IDR 16246.25
ILS 3.611275
IMP 0.739085
INR 85.14205
IQD 1307.824251
IRR 42125.000352
ISK 127.660386
JEP 0.739085
JMD 158.648898
JOD 0.70904
JPY 142.56504
KES 129.023178
KGS 87.450384
KHR 3996.129657
KMF 434.503794
KPW 899.99999
KRW 1365.730383
KWD 0.30651
KYD 0.831948
KZT 510.612658
LAK 21569.248362
LBP 89450.587149
LKR 298.887276
LRD 199.665743
LSL 17.869728
LTL 2.95274
LVL 0.60489
LYD 5.454545
MAD 9.176848
MDL 17.310991
MGA 4464.08937
MKD 54.123235
MMK 2099.29213
MNT 3575.367348
MOP 8.051722
MRU 39.703567
MUR 45.710378
MVR 15.460378
MWK 1731.09909
MXN 19.243604
MYR 4.231039
MZN 63.910377
NAD 17.869728
NGN 1589.803725
NIO 36.741874
NOK 10.106304
NPR 136.163082
NZD 1.670704
OMR 0.384879
PAB 0.998373
PEN 3.652637
PGK 4.092888
PHP 55.370375
PKR 281.388398
PLN 3.746678
PYG 7964.990984
QAR 3.638739
RON 4.446204
RSD 103.109469
RUB 79.342042
RWF 1430.091921
SAR 3.750687
SBD 8.350767
SCR 14.316752
SDG 600.503676
SEK 9.532404
SGD 1.287304
SHP 0.785843
SLE 22.720371
SLL 20969.500214
SOS 570.523816
SRD 37.177504
STD 20697.981008
SVC 8.735541
SYP 13001.79373
SZL 17.865154
THB 32.503038
TJS 10.232924
TMT 3.505
TND 2.984123
TOP 2.342104
TRY 38.853504
TTD 6.786295
TWD 29.972304
TZS 2692.96741
UAH 41.440296
UGX 3644.280248
UYU 41.474249
UZS 12882.966091
VES 94.846525
VND 25954
VUV 120.843118
WST 2.68961
XAF 576.995206
XAG 0.029862
XAU 0.000298
XCD 2.70255
XDR 0.717597
XOF 576.995206
XPF 104.903901
YER 243.850363
ZAR 17.84386
ZMK 9001.203587
ZMW 27.304394
ZWL 321.999592
  • SCS

    -0.0600

    10.09

    -0.59%

  • CMSD

    0.1600

    21.89

    +0.73%

  • AZN

    0.4600

    70.41

    +0.65%

  • GSK

    -0.2600

    38.66

    -0.67%

  • RYCEF

    0.1200

    11.32

    +1.06%

  • RIO

    0.4600

    61.58

    +0.75%

  • NGG

    1.1600

    74.79

    +1.55%

  • BTI

    0.6200

    45.22

    +1.37%

  • RBGPF

    65.0500

    65.05

    +100%

  • CMSC

    -0.0200

    21.94

    -0.09%

  • BCC

    -0.7700

    86.56

    -0.89%

  • JRI

    0.0500

    12.69

    +0.39%

  • RELX

    0.4600

    55.44

    +0.83%

  • BCE

    0.0600

    21.53

    +0.28%

  • VOD

    -0.0700

    10.47

    -0.67%

  • BP

    0.1500

    29.09

    +0.52%

Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman, Nobel-winning mRNA pioneer / Photo: © AFP

Drew Weissman, Nobel-winning mRNA pioneer

Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.

Text size:

The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.

His next quests include, among others, developing a vaccine against all future coronaviruses.

"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.

"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."

- Twin breakthroughs-

The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.

But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.

"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.

In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.

"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.

"We sat there staring at our phones for five years, and they never rang!"

With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."

Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.

- Helping people -

Weissman grew up in Lexington, Massachusetts.

His father and mother, both since retired, were an engineer and dental hygienist, respectively.

"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.

He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.

As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.

Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.

"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.

Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.

Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.

Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.

Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.

N.Wan--ThChM